Systemic Peptide Therapy Reduces Brain Damage After Stroke in Mice

Researchers tested IKVAV-PA, a peptide-based nanomaterial, in a mouse model of acute ischemic stroke and found that systemic delivery allows the molecules to cross the blood-brain barrier and reduce brain tissue damage, inflammation, and harmful immune responses after reperfusion, indicating potential as an adjunct therapy—though human safety and long-term efficacy remain to be studied.